Semigran Marc

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
South San Francisco, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ John R. Moore, Attorney-in-Fact for Semigran Marc
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Semigran Marc

Form 4 holding Chief Development Officer

Edgewise Therapeutics, Inc.

Security class
Restricted Stock Units
Shares / value
23,125
Estimated value
$437,294
Report date
12 Aug 2024
Price
$18.91
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Development Officer

Edgewise Therapeutics, Inc.

Security class
Common Stock
Shares / value
6,716
Estimated value
$202,019
Report date
24 Dec 2024
Price
$30.08
Ownership
Direct
Form 4 holding Chief Development Officer

Edgewise Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
270,291
Estimated value
Report date
24 Dec 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Medical Officer

Renovacor, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
01 Dec 2022
Price
$8.00
Ownership
Direct
Form 4 holding Chief Medical Officer

Renovacor, Inc.

Security class
Stock Option
Shares / value
0
Estimated value
Report date
01 Dec 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Semigran Marc

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .